Stitz L, Planz O, Bilzer T
Institut für Impfstoffe, Bundesforschungsanstalt für Viruskrankheiten der Tiere, Tübingen, Germany.
Med Microbiol Immunol. 1998 Mar;186(4):195-200. doi: 10.1007/s004300050064.
The antiviral effect of amantadine (1-aminoadamantane) was tested in vitro as well as in vivo. Treatment of persistently Borna disease virus (BDV)-infected cell lines of different origin and for various length of time did not result in a general reduction of virus titer or clearance of virus from infected cells. In vivo, rats were treated with amantadine by daily oral application or by use of osmotic pumps, and in both cases treatment was started before infection. Neither route of application of the drug had any influence on the time of onset of disease, on antiviral antibody titers, on virus titer in the brain, on the severity of the inflammatory reaction in the brain, or on the severity of neurological symptoms. These experiments, although revealing negative results and obtained using a virus from a natural case of Borna disease grown after isolation in vitro for a long period of time, should caution from the general use of amantadine as a curative agent against BDV infection as has been implicated recently [Bode et al. (1997) Lancet 349:178-179].
金刚烷胺(1-氨基金刚烷)的抗病毒作用在体外和体内均进行了测试。用金刚烷胺处理不同来源且感染不同时长的持续性博尔纳病病毒(BDV)感染细胞系,并未导致病毒滴度普遍降低或病毒从感染细胞中清除。在体内,通过每日口服或使用渗透泵给大鼠施用金刚烷胺,两种情况下均在感染前开始治疗。药物的任何一种施用途径对疾病发作时间、抗病毒抗体滴度、脑中病毒滴度、脑内炎症反应严重程度或神经症状严重程度均无任何影响。这些实验虽然得出了阴性结果,且使用的病毒是从体外长期培养的博尔纳病自然病例中分离得到的,但鉴于最近有人暗示[博德等人(1997年)《柳叶刀》349:178 - 179],应谨慎对待将金刚烷胺作为治疗BDV感染的药物普遍使用。